CAMBRIDGE, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome
editing company, today announced that management will present a company overview at two upcoming investor conferences in
February. Details of the presentations are as follows:
| 19th Annual BIO CEO & Investor
Conference |
| Date: |
Monday, February 13, 2017 |
| Time: |
3:00 p.m. ET |
| Location: |
New York City |
| |
|
| RBC Capital Markets 2017 Global Healthcare
Conference |
| Date: |
Wednesday, February 22, 2017 |
| Time: |
10:30 a.m. ET |
| Location: |
New York City |
Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at
www.editasmedicine.com. Archived replays will be available for approximately 30 days
following the respective presentations.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting
their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the
promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of
patients.
Media Contact Dan Budwick
Pure Communications, Inc.
(973) 271-6085 dan@purecommunicationsinc.com Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 mark.mullikin@editasmed.com
